the presence of pro-inflammatory cytokine interleukin Ip, which induces endothelial responsiveness to the in vitro effects of HIV-Tat. We have previously shown that EDF-1 is cytosolic and can be translocated to the nucleus upon activation of protein kinases A and C. In response to HIV-Tat, EDF-1 is mainly in the cytosol. Since cytosolic EDF-l binds and sequesters calmodulin, an important regulator of endothelial nitric oxide synthase, these results might explain why we do not observe any induction of nitric oxide in endothelial cells exposed to HIV-Tat.
Human immunodeficiency virus-l (HIV)-Tat is a viral protein released by infected T cells and plays a critical role in the trans-activation of HIV-I replication (l). HIV-Tat exhibits a wide variety of other activities, including immune suppression, growth modulation, and gene activation. Endothelial cells are one of the targets of HlV-Tat (2) , and have been implicated in the dissemination of HIV-l (3). HIV-Tat induces endothelial growth and migration (4-5) and expression of adhesion molecules (6) . It has been shown that HIV-Tat binds vascular endothelial growth factor receptor type 2, likely through its basic domain (5) . Furthermore, full activation of the angiogenic program requires the HIV-Tat C-terminal region containing the arginineglycine-aspartic sequence, which represents the principal cell attachment moiety recognized by integrin receptors (7) .
Since HIV-Tat affects endothelial cell function, we assumed that the isolation of differentially expressed genes in HIV-Tat-treated endothelial cells would yield insights into the molecular mechanisms contributing to endothelial dysfunction in AIDS-associated Kaposi's sarcoma (KS) and, more generally, in angiogenesis. Endothelial Differentiating Factor 1 (EDF-l, also denominated hMBFl) was isolated by RNA fingerprinting as a novel factor differentially expressed in the HIV-Tat treated endothelial cell line ECV-304 (8) . EDF-l, highly conserved and ubiquitously distributed, is downregulated KS spindle cells, which suggest it could play a role in AIDS-associated KS (8) (9) . In addition, transfection of human endothelial cells derived from the umbilical vein (HUVEC) with an antisense EDF-l eDNA resulted in the inhibition of endothelial cell growth and in the transition from a non-polar cobblestone phenotype to a polar, fibroblast-like phenotype, thus mimicking the early steps of in vitro endothelial cell differentiation pathway (8) . Based on the evidence that EDF-l is both cytosolic and nuclear (10) (11) (12) , we have shown that EDF-l serves different functions in HUVEC. Indeed, cytosolic EDF-l binds calmodulin, whereas nuclear EDF-1 functions as a transcriptional coactivator through its interaction with different transcription factors (10) (11) 13) .
Here we describe that HIV-Tat downregulates EDF-l RNA by acting on EDF-l promoter in HUVEC. The inhibition of transcription, however, does not result into a modulation EDF-1 at the protein level.
MATERIALS AND METHODS

Cell culture and transfections
HUVEC were isolated from the umbilical vein and serially passaged in Ml99 containing 10% FCS, Napyruvate, ECGF (150 ug/ml) and heparin (5 U/ml) on 2% gelatin coated dishes. The cells were routinely evaluated for the expression ofendothelial markers, i.e. VE-cadherin and CD34, and utilized for 5-6 passages (9). HIV-Tat was from Intracel (Cambridge, MA).
Optimem was used in transfection reactions. In transient transfection assays, 10 5 HUVEC were transfected with 1 ug of the pGL2/0 1 reporter construct (14) , using Lipofectin (Invitrogen), according to the manufacturer's instructions. 0.5 ug of pCMV-pGal plasmid were cotransfected to normalize luciferase activity. 20 h after transfection, cells were treated with different concentrations of HIV-Tat for 30 min and harvested for luciferase assay in 200 ul ofcold lysis buffer (25 mM glycil-glycine pH 7.8, 1% v/v Triton X 100, 15 mM MgS0 4 , 4 mM EGTA, 1 mM DTT) (14) . Data are expressed as the mean ± standard deviation. Statistical analysis was performed using the GraphPad InStat software, and differences were considered significant when P<0.05.
Immunofluorescence
Cells were cultured on coverslips for 24 hr, washed with PBS and fixed in 3% paraformaldehydel 2% sucrose in PBS for 10 min at room temperature. Cells were then washed with PBS, permeabilized with HEPES Triton X-100 buffer (20 mM HEPES, 300 mM sucrose, 50 mM NaCl, 3 mM MgCI 2 , 0.5 % Triton X-I 00) and washed again in PBS. Cells were incubated at 37°C in 2% bovine serum albumin (BSA) in PBS for 40 min prior to incubation (30 min) with the appropriate primary antibody diluted in PBS containing 2% BSA. After extensive washing, EDF-1 was detected with FITC-labelled anti-rabbit (Sigma).
RT-PCR
TotalRNAwas extracted with Trizol reagent (SIGMA). 1 ug of RNA was reverse transcribed and amplified by PCR. The sequences of the primers for EDF-l are the following: 5' -ATCTTAGCGGCACAGAGACGAGG-3' (forward); 5' -GAACCGGCGGAACGAGATCAGC-3' (reverse).
Western blot
HUVEC were lysed in 100 mM Tri-.Hcl (pH 6.8) containing 4% SDS, 20% glycerol and protein inhibitors and centrifuged for 20' at 13000 rpm at room temperature. Cell extracts were separated on 15% SDS-PAGE and transferred to nitrocellulose sheets. Western analysis was performed using polyclonal anti-EDF-1 (Aviva System Biology). Secondary antibodies were labeled with horseradish peroxidase (GE Healthcare). The SuperSignal chemiluminescence kit (Pierce) was used to detect immunoreactive proteins. The blots were stripped and incubated with an anti-actin antibody (Santa Cruz-Tebu-bio) to show that comparable amounts of protein were loaded per lane. In some experiments, nuclear and cytoplasmic extracts were obtained as previously described (12) and processed by western blot. All the experiments were repeated at least three times with comparable results.
RESULTS
The effect ofHIV-Tat on EDF-l RNA
We exposed HUVEC to HIV-Tat (50 ng/ml) for different times and evaluated EDF-l expression by RT-PCR. Fig. lA shows that EDF-l RNA is downregulated 30 min, 1 and 4 h after the treatment, and returns to basal levels after 12 h. To understand the mechanisms involved in the downregulation of EDF-l RNA by HIV-Tat, we transiently transfected HUVEC with a construct containing 2300 bp of EDF-l promoter cloned upstream of a luciferase reporter system (14) . The cells were then exposed to different concentrations of HIV-Tat for 30 min. The effect ofHIV-Tat on EDF-l cellular distribution EDF-l can be localized both in the cytosol and in the nucleus (10) (11) (12) . We have shown that a 30 min exposure to the phorbol ester TPA or to Indeed, HIV-Tat binds and phosphorylates the VEGF receptor type 2 (5) . It has also been demonstrated that some of the effects of extracellular HIV-Tat Oft the endothelial cells are due to its ability to biRd forskolin induces EDF-l nuclear translocation (10) . We therefore evaluated whether HIV-Tat for 30 min alters EDF-1 subcellular localization. By immunofluorescence, we found that EDF-l is mainly perinuclear both in controls and HIV-Tattreated cells (Fig. 3) .
The effect of IL-l and HIV-Tat on EDF-l at the protein level
Because HIV infection promotes an inflammatory environment and IL-l~enhances endothelial sensitivity to HIV-l tat (16), we treated HUVEC with IL-l~(50 ng/ml) and HIV-Tat (50 ng/ml) alone or in combination for 12 h. Fig. 4 shows that no alterations of the levels ofEDF-l occurs as detected by western blot.
Fig. 2. HIV-Tat does not modulate EDF-J at the protein level, (A) HUVEC were treated with HIV-Tat (50 ng/ml) for different times and analyzed for EDF-J levels by
western blot, (B) HUVEC were exposed to HIV-Tat (50 ng/ml) in the presence or in the absence of MG J32 (l0 flM) for J6 h. Western blots were performed on J00 flg of cell lysate as described. Incubation with an anti-actin antibody shows that comparable amounts ofprotein were loaded. 
B
The effect ofHIV-Tat on EDF-l at the protein level To evaluate whether the downregulation ofEDF-I RNA translated into a modulation of the protein, we exposed HUVEC to HIV-Tat (50 ng/ml) for different times and performed a western blot using specific antibodies against EDF-l. Fig. 2A shows no modulation ofEDF-l. Since i) the proteasome has a role in the degradation of EDF-1 (12) and ii) HIV-Tat affects proteasome activity (15) , we treated HUVEC with HIV-Tat in the presence of MG 132 (10 J,tM), a proteasome inhibitor. We found no modulation of the total amounts ofEDF-1 by western analysis (Fig.  2B ). control M . MARIOTII ET AL. integrin s a5~1 and av~3 (17) . These events elicit different signal transduction pathways which lead to a transcriptional reprogramming of the endotheli al cells. We found that extracellular HIV-Tat downmodulates EDF-I RNA through an inhibition of its promoter activity. Recentl y, we characterized the EDF-I promoter sequence and demonstrated that NF-Y and Sp l/Sp3 binding is essential for its activity (14) . Since HIV-Tat has been shown to suppress manganese superoxide dismutase expression by modulating Sp l/Sp3 activity in hepatocellular carcinoma cells (18) , we argue that HIV-Tat might activate intracellular signals that interfere with the binding of Sp l/Sp3 to the EDF-I promoter. The downregulation of EDF-I RNA, however, does not translate into a decrease of EDF-I at the protein level. This could be due to the fact that the inhibition of EDF-l transcription by HIV-Tat is transient since we show that within 12 h the amounts of EDF-l RNA revert to the pre-treatment levels. We also hypothe size that HIV-Tat might stabilize EDF-I, i.e. by contrasting its degradation . Indeed , recently we have shown that the proteasome, the major housekeeping proteolytic complex responsible for eliminating intracellular proteins (19) , is involved in the regulation of the total amounts of EDF-I in senescent and quiescent murine endothelial cells (12) . However, we found that the proteasome inhibitor MGl32 is unable to upregulate EDF-l in endothelial cells exposed to HIV-Tat. This is in keeping with preliminary experiments showing no alterations of the proteasome activity in Tat-treated cells (not shown). Because i) HIV infection promotes a pro-inflammatory environment (16) and ii) inflammatory cytokines, including IL-l s, induce endothelial responsiveness to the in vitro effects of Tat (20) , we evaluated whether IL-lc ould potentiate the effect of HIV-Tat. Again, we did not observe any modulation of the total amounts of EDF-l in HUVEC treated with the two proteins. All together these results suggest that EDF-1 is rather stable. More experiments are required to highlight this issue. In endothelial cells treated or not with HIV-Tat, EDF-1 is localized both in the nucleus and in the cytosol. Interestingly, cytosolic EDF-1 binds calmodulin. Since EDF-l releases calmodulin in the cytosol and accumulates in the nucleus within 30 min from the activation of protein kinase C and A (10-11), we rule out an activation of these kinases by extracellular HIV-Tat. Calmodulin is the principal Ca 2 + receptor protein inside the cell and its calciumrich form activates a large array of enzymes that are part of intracellular signaling cascades controlling cellular homeostasis, among which endothelial nitric oxide synthase (eNOS). We have shown in vitro that recombinant EDF-l inhibits the activity ofNOS (11). Accordingly, in endothelial cells downregulating EDF-l, we detected an increase of NOS activity (11). In keeping with the results showing that EDF-l remains in the cytosol after exposure to HIV-Tat, we did not detect any modulation ofNO synthesis in our system (not shown). Interestingly, NO production is markedly increased in HIV infected individuals. While it is possible that other cell types are involved in the production of NO, we hypothesize that in HIV infected patients the chronic exposure of the endothelium to HIV-Tat might lead to a stable downregulation of EDF-l mRNA. The consequent reduction of the total amounts of EDF-l might release free calmodulin which would ultimately induce the activation of endothelial nitric oxide synthase. This could be a relevant issue to evaluate since NO plays a role in the pathogenesis of some HIV-related diseases as well as in viral replication.
HIV-tat (30')
